These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 34363915

  • 1. Co-amorphization of atorvastatin by lisinopril as a co-former for solubility improvement.
    Li W, Song J, Li J, Li M, Tian B, He Z, Liu X, Fu Q.
    Int J Pharm; 2021 Sep 25; 607():120971. PubMed ID: 34363915
    [Abstract] [Full Text] [Related]

  • 2. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
    Jensen KT, Blaabjerg LI, Lenz E, Bohr A, Grohganz H, Kleinebudde P, Rades T, Löbmann K.
    J Pharm Pharmacol; 2016 May 25; 68(5):615-24. PubMed ID: 26245703
    [Abstract] [Full Text] [Related]

  • 3. [Co-amorphous technology to improve dissolution and physical stability of silybin].
    Liu H, Zhao GW, Jiang QY, Liang XL, Ouyang LQ, Ding HB, Chen XL, Liao ZG.
    Zhongguo Zhong Yao Za Zhi; 2022 Jan 25; 47(1):103-110. PubMed ID: 35178916
    [Abstract] [Full Text] [Related]

  • 4. [The development of co-amorphous drug systems].
    Yao J, Shi NQ, Wang XL.
    Yao Xue Xue Bao; 2013 May 25; 48(5):648-54. PubMed ID: 23888685
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The influence of amorphization methods on the apparent solubility and dissolution rate of tadalafil.
    Wlodarski K, Sawicki W, Paluch KJ, Tajber L, Grembecka M, Hawelek L, Wojnarowska Z, Grzybowska K, Talik E, Paluch M.
    Eur J Pharm Sci; 2014 Oct 01; 62():132-40. PubMed ID: 24907679
    [Abstract] [Full Text] [Related]

  • 10. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
    Huang Y, Zhang Q, Wang JR, Lin KL, Mei X.
    Pharm Dev Technol; 2017 Feb 01; 22(1):69-76. PubMed ID: 27050301
    [Abstract] [Full Text] [Related]

  • 11. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH, Gordon S, Holm R, Selen A, Rades T, Müllertz A.
    Eur J Pharm Biopharm; 2013 Nov 01; 85(3 Pt B):942-51. PubMed ID: 24075980
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Development of the Binary and Ternary Atorvastatin Solid Dispersions: In Vitro and In Vivo Investigations.
    Faraji E, Mohammadi M, Mahboobian MM.
    Biomed Res Int; 2021 Nov 01; 2021():6644630. PubMed ID: 34527740
    [Abstract] [Full Text] [Related]

  • 14. Potential application of low molecular weight excipients for amorphization and dissolution enhancement of carvedilol.
    Pešić N, Dapčević A, Ivković B, Kachrimanis K, Mitrić M, Ibrić S, Medarević D.
    Int J Pharm; 2021 Oct 25; 608():121033. PubMed ID: 34419592
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Co-amorphous systems of sulfasalazine with matrine-type alkaloids: Enhanced solubility behaviors and synergistic therapeutic potential.
    Chen X, Qin Y, Wang L, Zhu Y, Zhang H, Liu W, Zeng M, Dai Q.
    Eur J Pharm Biopharm; 2024 Oct 25; 203():114475. PubMed ID: 39216557
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Physicochemical Characterization of a Co-Amorphous Atorvastatin-Irbesartan System with a Potential Application in Fixed-Dose Combination Therapy.
    Skotnicki M, Jadach B, Skotnicka A, Milanowski B, Tajber L, Pyda M, Kujawski J.
    Pharmaceutics; 2021 Jan 18; 13(1):. PubMed ID: 33477672
    [Abstract] [Full Text] [Related]

  • 20. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process.
    Kim MS, Jin SJ, Kim JS, Park HJ, Song HS, Neubert RH, Hwang SJ.
    Eur J Pharm Biopharm; 2008 Jun 18; 69(2):454-65. PubMed ID: 18359211
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.